• Wnt Agonist 1 (BML-284): Optimizing Wnt Pathway Research Wor

  2026-05-19

  Wnt agonist 1 (BML-284) delivers precise, reproducible activation of the canonical Wnt signaling pathway, enabling robust investigation of cellular differentiation and chemoresistance mechanisms. Discover practical protocols, advanced troubleshooting, and translational applications that set this APExBIO reagent apart for developmental and cancer biology research.

• PP 1 Src Family Tyrosine Kinase Inhibitor: Protocols & Preci

  2026-05-18

  PP 1 enables selective dissection of Src kinase-driven signaling in cancer and immunology, empowering both mechanistic and translational research. This guide delivers actionable protocols, troubleshooting insights, and a synthesis of recent breakthroughs—anchored by evidence from cardiac and oncologic studies—to help researchers unlock the full experimental potential of PP 1.

• Olive Biophenols Attenuate Amyloid Pathology in Alzheimer’s

  2026-05-18

  This study demonstrates that olive biophenols, particularly oleuropein, verbascoside, and rutin, significantly reduce amyloid beta aggregation and neurotoxicity in both neuronal cell and mouse models of Alzheimer’s disease. The findings highlight the translational potential of natural biophenols as disease-modifying agents and set the stage for further mechanistic and bioavailability research.

• Clathrin-Mediated Entry of Grass Carp Reovirus: Inhibitor In

  2026-05-17

  Wang et al. (2018) elucidate that type III grass carp reovirus (GCRV104) enters host cells through clathrin-mediated, pH-dependent endocytosis, using a suite of pharmacological inhibitors to dissect the pathway. The study highlights the role of PI3K inhibition by Wortmannin in blocking viral entry, underscoring both mechanistic advances and potential avenues for antiviral research.

• Targeted CRISPRi Delivery to Adipocytes: Obesity and Metabol

  2026-05-16

  This study demonstrates a targeted nonviral CRISPR interference (CRISPRi) system to silence Fabp4 selectively in white adipocytes, leading to amelioration of obesity, inflammation, hepatic steatosis, and insulin resistance in obese mice. The innovation lies in the use of an adipocyte-targeted delivery platform, offering improved precision and reduced side effects compared to conventional anti-obesity therapies.

• Strategic NOS Inhibition: L-NMMA Acetate for Translational I

  2026-05-15

  This thought-leadership article explores how L-NMMA acetate (N(G)-monomethyl-L-arginine acetate) enables translational researchers to precisely interrogate the nitric oxide pathway, with mechanistic insights, protocol guidance, and strategic context. By synthesizing recent evidence, including the pivotal role of nitric oxide in stem cell differentiation and inflammatory modulation, we outline advanced applications, workflow parameters, and future directions for disease modelers and regenerative medicine innovators. This analysis goes beyond conventional product pages by integrating cross-domain evidence and offering actionable, evidence-labeled advice.

• Syringin Natural Product: Optimizing RCC Bioactive Screening

  2026-05-15

  Harnessing the Syringin natural product streamlines apoptosis research and bioactive compound screening in renal cell carcinoma (RCC). Recent evidence shows Syringin enhances sunitinib efficacy via EGFR/PI3K/Akt inhibition, offering researchers a robust tool for overcoming drug resistance.

• Radiotherapy Plus Dual Checkpoint Blockade Drives Abscopal I

  2026-05-14

  This study demonstrates that combining radiotherapy with PD-1 and TIGIT immune checkpoint blockade induces robust abscopal antitumor effects and long-lasting immune memory via CD8+ T cells in murine models. The findings clarify cellular and molecular mechanisms of synergy, with implications for overcoming resistance in cancer immunotherapy.

• EZ Cap™ Human PTEN mRNA (ψUTP): Protocols for Cancer Researc

  2026-05-14

  EZ Cap™ Human PTEN mRNA (ψUTP) delivers robust, immune-evasive PTEN restoration ideal for translational oncology workflows. This article details experimental protocols, troubleshooting tactics, and the practical impact of cutting-edge nanoparticle delivery in overcoming PI3K/Akt-driven drug resistance.

• Jiedu Xiaozheng Yin Drives M1 Macrophage Polarization via TL

  2026-05-13

  This study by Liu et al. demonstrates that Jiedu Xiaozheng Yin (JXY), a traditional Chinese medicine compound, suppresses colitis-associated colorectal cancer (CAC) progression by promoting macrophage polarization towards the pro-inflammatory M1 phenotype through TLR4 signaling. The findings reveal mechanistic insights into immunomodulation within the tumor microenvironment, providing a foundation for future chemopreventive strategies targeting innate immunity.

• Patient-Derived Gastric Cancer Assembloids Reveal Tumor-Stro

  2026-05-13

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations. The approach enhances the physiological relevance of preclinical drug screening and deepens the understanding of tumor heterogeneity and drug resistance mechanisms.

• WZ4003: Applied Protocols for NUAK1/2 Inhibitor-Based Cell A

  2026-05-12

  WZ4003 unlocks highly selective NUAK1/2 inhibition for dissecting cell migration, proliferation, and tau phosphorylation in cancer and neurodegeneration models. This guide delivers actionable, literature-backed protocols, troubleshooting insights, and cutting-edge applications based on real-world experimental outcomes.

• Y-27632: Unraveling ROCK Inhibition for Immunomodulation

  2026-05-12

  Explore how Y-27632, a selective ROCK inhibitor, is revolutionizing cytoskeletal dynamics and immune pathway research. Discover its advanced applications in cancer metastasis models and the latest mechanistic insights bridging cytoskeletal modulation and immunotherapy.

• Pazopanib (GW-786034): Multi-Targeted RTK Inhibitor for Canc

  2026-05-11

  Pazopanib (GW-786034) is a potent, selective multi-targeted receptor tyrosine kinase inhibitor used for angiogenesis inhibition and tumor growth suppression in cancer research. It exhibits nanomolar activity against VEGFR, PDGFR, and FGFR, with robust in vitro and in vivo benchmarks. This dossier summarizes its mechanism, evidence, and protocol guidance for translational oncology.

• BMS-345541: Precision IKK-1/2 Inhibition for Advanced Inflam

  2026-05-11

  Explore how BMS-345541, a selective IKK-1/IKK-2 inhibitor, enables advanced inflammation and angiogenesis research. This article offers a deeper, protocol-focused look at practical assay design and translational implications, surpassing existing coverage.

16279 records 1/1086 page Next 12345 下5页 Last page